Cardiometabolic Labels Reach Millions — The addressable population just jumped by two orders of magnitude. Tryngolza started as a drug for familial chylomicronemia syndrome, which affects an estimated 6,500 people in the U.S., and in June 2026 the FDA approved it for severe hypertriglyceridemia, a condition that affects more than 3 million Americans, about 1 million of them at high risk of acute pancreatitis. Arrowhead's Redemplo follows the same path after its November 2025 FCS approval, with Phase 3 SHASTA-3/4 sHTG data reported in July 2026. Novartis's twice-yearly siRNA Leqvio grew sales 57% in 2025 in LDL-cholesterol lowering. Cardiometabolic Disease is the fastest-growing application, rising from USD 1,209.3 Mn in 2025 to USD 5,423.5 Mn by 2035 at a 16.19% CAGR. Expect more of the market's growth to come from primary-care-adjacent cardiology than from ultra-rare indications.
Oligonucleotide Therapeutics Market Report: Size, Share & Trends
Oligonucleotide Therapeutics Market by Type (Antisense Oligonucleotides, siRNA, Aptamers, CpG Oligonucleotides, Splice-switching oligonucleotides, microRNA mimics and inhibitors), by Application (Neurological Disorders, Oncology, Cardiometabolic Disease, Rare Genetic Disease, Ophthalmic, infectious and autoimmune diseases), by Route of Administration (Subcutaneous, Intravenous, Intrathecal, Intravitreal, intramuscular, intranasal and inhaled routes), by End User (Hospitals & Specialty Clinics, Biopharma Manufacturers, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
Oligonucleotide Therapeutics Industry Perspective
The Global Oligonucleotide Therapeutics market was valued at USD 6,718.5 Mn in 2025 and is projected to reach USD 20,718.1 Mn by 2035, growing at a CAGR of 11.92% during the forecast period 2026–2035, according to Vectomat Insights.
North America is the dominant region at 39.76% of 2025 revenue, Antisense Oligonucleotides are the largest type at 44.0%, and siRNA is on course to overtake antisense in value before 2035 as GalNAc-conjugated drugs move into cardiology.
Oligonucleotide Therapeutics Market: Overview
The Oligonucleotide Therapeutics Market encompasses synthetic nucleic-acid drugs that act on RNA or immune receptors: antisense oligonucleotides, small interfering RNA (siRNA), aptamers, CpG oligonucleotides, and splice-switching oligonucleotides and microRNA mimics and inhibitors. The scope covers approved and launched products across neurological, oncology, cardiometabolic, rare genetic, ophthalmic, infectious and autoimmune indications, delivered by subcutaneous, intravenous, intrathecal and other routes.
The value chain runs across three tiers. Foundational providers such as ST Pharm and Bachem make oligonucleotide API at commercial scale. Specialist developers, including Arrowhead Pharmaceuticals, Wave Life Sciences and Dyne Therapeutics, build delivery and chemistry platforms. Application-layer specialists such as Ionis Pharmaceuticals, Alnylam Pharmaceuticals and Biogen own approved drugs and the commercial relationships with neurologists, cardiologists and specialty pharmacies.
For procurement and investment decision-makers, value concentrates in subcutaneous cardiometabolic siRNA, intrathecal neurology and the CDMOs that supply both. This report breaks the market into 4 segmentation dimensions and covers 35+ countries across six regions, from North America to Africa.

Key Insights
- The Global Oligonucleotide Therapeutics market grows from USD 6,718.5 Mn in 2025 to USD 20,718.1 Mn by 2035, an 11.92% CAGR over 2026–2035.
- Antisense Oligonucleotides are the dominant type at 44.0% of 2025 revenue (USD 2,956.1 Mn), while siRNA, at 36.0%, rises to USD 8,781.3 Mn by 2035 and overtakes antisense.
- Splice-switching oligonucleotides, microRNA mimics and inhibitors are the fastest-growing type, at a 19.13% CAGR from USD 268.7 Mn, helped by conjugated exon skippers such as Dyne's z-rostudirsen.
- Neurological Disorders are the dominant application at 32.0% (USD 2,149.9 Mn), because intrathecal antisense drugs such as Spinraza are dosed for life; Cardiometabolic Disease grows fastest, at 16.19%.
- Hospitals & Specialty Clinics are the dominant end user at 53.4% of revenue, since intrathecal and intravenous drugs need specialist administration; Biopharma Manufacturers grow at 17.35% and become the largest end user by 2035.
- North America leads with 39.76% of 2025 revenue (USD 2,671.5 Mn), with the United States at USD 2,096.2 Mn.
- Asia Pacific is the fastest-growing region, with South Korea growing at a 14.1% CAGR to about USD 1,206.1 Mn by 2035 on the back of oligonucleotide API manufacturing.
- Big pharma is buying delivery technology: Novartis's USD 12.0 billion Avidity acquisition and Sanofi's USD 2.2 billion Dynavax deal both completed in 2026.
- Two 2026 outcome-trial misses, in ATTR cardiomyopathy and Lp(a), mean the cardiometabolic shift will run through triglyceride and LDL indications first.

Oligonucleotide Therapeutics Market: Report Scope
| Report Name | Oligonucleotide Therapeutics Market by Type (Antisense Oligonucleotides, siRNA, Aptamers, CpG Oligonucleotides, Splice-switching oligonucleotides, microRNA mimics and inhibitors), by Application (Neurological Disorders, Oncology, Cardiometabolic Disease, Rare Genetic Disease, Ophthalmic, infectious and autoimmune diseases), by Route of Administration (Subcutaneous, Intravenous, Intrathecal, Intravitreal, intramuscular, intranasal and inhaled routes), by End User (Hospitals & Specialty Clinics, Biopharma Manufacturers, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035 |
|---|---|
| Market Size in 2025 | USD 6,718.5 Mn (2025) |
| Market Forecast in 2035 | USD 20,718.1 Mn (2035) |
| Growth Rate (CAGR) | 11.92% |
| Historical Data Period | 2023–2025 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| Number of Pages | 300+ |
| Tables & Figures | 98 tables & 72 figures |
| Report Code | VMI-1-1-15389 |
| Report Format | |
| Delivery Format | PDF via email delivery and online download portal |
| Published Date | November 2026 |
| Research Methodology | Primary interviews + secondary research + verified market sizing (top-down and bottom-up triangulation) |
| Key Companies Covered | Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Biogen, Novartis, Sanofi, AstraZeneca, Astellas Pharma, Nippon Shinyaku, Arrowhead Pharmaceuticals, Wave Life Sciences, Dyne Therapeutics, City Therapeutics, ST Pharm, Bachem |
| Segments Covered | Type, Application, Route of Administration, End User |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, The Middle East, Africa |
| Customization Scope | Up to 10% free customization: additional country splits, extra company profiles, or deeper sub-segment cuts (for example by chemistry, conjugate type or target organ) on request |
Why This Oligonucleotide Therapeutics Market Report Matters
Decision-makers comparing market intelligence reports on Oligonucleotide Therapeutics will find the VMI report differentiated on the following dimensions.
| Dimension | VMI Report | Industry Average |
|---|---|---|
| Report Pages | 300+ | ~120 pages |
| Forecast Horizon | 10 years | 7 years |
| Segmentation Dims | 4 dims | 4-5 dimensions |
| Historical Data | 3 years | 4-5 years |
| Country Coverage | 35+ countries | 15-18 countries |
| Companies Profiled | 15 companies | 10-12 companies |
| DROC Framework | Full (4 elem) | Drivers only |
For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com
Why Is the Oligonucleotide Therapeutics Market Growing?
Rare Disease Approvals Keep Coming — Rare disease is still where oligonucleotide chemistry proves itself first. In 2025 the FDA approved Sanofi's Qfitlia (fitusiran), the first siRNA for hemophilia A or B, in March, Alnylam's Amvuttra for transthyretin cardiomyopathy the same month, and Ionis's Dawnzera (donidalorsen) for hereditary angioedema in August. Each one targets a liver-expressed protein that a GalNAc or ligand conjugate can reach with infrequent subcutaneous dosing. Pricing in these indications supports high revenue per patient, and the July 2025 widening of the Medicare orphan-drug exclusion protects that pricing in the U.S. Rare Genetic Disease revenue grows from USD 940.6 Mn in 2025 to USD 2,629.5 Mn by 2035, a 10.83% CAGR.
Intrathecal Neurology Gains Depth — No other drug class reaches the spinal cord and brain as directly. Intrathecal antisense drugs such as Spinraza for spinal muscular atrophy and Qalsody for SOD1 ALS are dosed for life, and Spinraza alone had been given to more than 14,000 people worldwide by mid-2024. Neurological Disorders are the largest application, at 32.0% of 2025 revenue (USD 2,149.9 Mn), and grow at 13.51% a year to USD 7,633.7 Mn by 2035. Intrathecal is the fastest-growing route of administration, at an 18.47% CAGR, as Alnylam's mivelsiran and other CNS siRNA programs move into Alzheimer's disease and cerebral amyloid angiopathy. Biogen's FDA approval of a high-dose Spinraza regimen in March 2026 is the latest example.
New Manufacturing Capacity Comes Online — Capacity has become a growth input in its own right. Prevalent-disease launches need hundreds of kilograms of API a year, far more than the rare-disease drugs that built today's supply chain. Alnylam announced a USD 250 million investment in December 2025 to add its siRELIS enzymatic-ligation platform at Norton, Massachusetts, by late 2027, and ST Pharm won a KRW 89.7 billion oligonucleotide API order in March 2026. Bachem followed in July 2026 with plans for a large-scale plant at Sisslerfeld. Biopharma Manufacturers are the fastest-growing end user, rising at a 17.35% CAGR to USD 10,779.6 Mn by 2035. In structural terms, this is the point where oligonucleotides stop being a boutique chemistry and start behaving like a volume modality with scale economics.
The approval of TRYNGOLZA marks an historic advance for people who have long struggled to control their dangerously high triglycerides.
The FDA approval of REDEMPLO is a transformational milestone for Arrowhead. This approval, and subsequent launch, marks the beginning of a new chapter in our journey.
What's Limiting the Oligonucleotide Therapeutics Market?
Confirmatory Trials Under Scrutiny — Accelerated approval is a loan that has to be repaid with data. Sarepta's ESSENCE trial of Amondys 45 and Vyondys 53 in 225 Duchenne patients missed its primary endpoint at 96 weeks (P=0.309), and Sarepta now seeks traditional approval using real-world evidence. Nippon Shinyaku's Viltepso had already failed its confirmatory RACER53 study. Sarepta's PMOs have treated more than 1,800 patients over a decade, so the commercial exposure is real. Dyne's May 2026 BLA for z-rostudirsen and Avidity's del-zota filing will be judged in this climate. Expect the FDA to ask for functional outcomes sooner in the development of muscle-targeted oligonucleotides.
Outcome Trials Miss in Big Indications — Moving from biomarker to outcome is where the biggest bets fail. AstraZeneca reported in July 2026 that the CARDIO-TTRansform Phase III trial of eplontersen in transthyretin cardiomyopathy missed its primary endpoint, leaving Alnylam's Amvuttra alone in that indication among silencers. In September 2026 pelacarsen's Lp(a)HORIZON trial also missed, the first major Lp(a)-lowering outcomes study to fail. Both programs were built to take antisense into populations of hundreds of thousands. The setback slows, but doesn't stop, the cardiometabolic shift, and Cardiometabolic Disease still holds only 18.0% of 2025 revenue.
Costly Synthesis and Purification — The chemistry scales; the factory doesn't, at least not cheaply. Conventional solid-phase synthesis adds one nucleotide at a time, consumes large solvent volumes and needs chromatography to strip out failure sequences, and purification is widely described as the main capacity constraint. Prevalent-disease launches multiply API demand while payers push net prices down, so cost of goods matters far more than it did for ultra-rare drugs. Alnylam's cost of goods rose to 22.7% of net product revenue in 2025 from 18.6% in 2024. New capacity takes two to three years to qualify. Alnylam expects its siRELIS enzymatic-ligation platform to expand capacity and cut production costs once it is running by late 2027.
While the ESSENCE study did not meet statistical significance on its primary endpoint, we believe the results demonstrated a clear treatment effect.
Emerging Opportunities in the Oligonucleotide Therapeutics Market
Delivery Beyond the Liver — The liver is solved, and the value has moved to every other tissue. Novartis agreed in October 2025 to acquire Avidity Biosciences for about USD 12.0 billion, and the FDA accepted the BLA for Avidity's del-zota in exon 44 Duchenne muscular dystrophy in September 2026. Dyne filed z-rostudirsen in May 2026, and City Therapeutics raised USD 99.5 million in June 2026 for extrahepatic RNAi. Intravenous revenue, the route most conjugates use, grows at a 14.89% CAGR to USD 7,001.3 Mn by 2035. Muscle, heart and CNS indications should account for a rising share of approvals after 2028.
siRNA for Obesity and Metabolism — Obesity could become the largest test of infrequent siRNA dosing. Wave Life Sciences reported in March 2026 that one 240 mg dose of WVE-007, a GalNAc-siRNA against INHBE, cut visceral fat by 14.3% versus placebo at six months while preserving lean mass. Alnylam has its own adipose-targeted program, ALN-2232, in Phase 1. Twice-yearly or once-yearly dosing would suit maintenance after incretin therapy. Cardiometabolic Disease already grows at 16.19% a year without any obesity revenue in the base case.
China Licensing and Approvals — China is now both a source of siRNA assets and a launch market. Novartis signed a multi-asset siRNA licensing and option agreement worth up to USD 5.2 billion with Argo Biopharma in September 2025. On the approval side, the NMPA cleared Sanofi's Qfitlia in December 2025 and Redemplo in early 2026. Asia Pacific is the fastest-growing region, and its biotech developers are licensing cardiovascular siRNA programs to Western buyers at early stages. Argo's deal with Novartis is the template.
Individualised Antisense Pathway — A drug made for one patient needs its own regulatory logic. In November 2025, FDA Commissioner Marty Makary and CBER Director Vinay Prasad outlined a 'plausible mechanism' pathway for bespoke therapies, including individualised antisense oligonucleotides for ultra-rare mutations. Academic centres and nonprofits design these drugs today, often for a single child. Academic & Research Institutes account for 14.2% of 2025 revenue and grow at 11.99% a year. In practice, the pathway turns antisense from a product into a platform service.
What's Holding Back the Oligonucleotide Therapeutics Market?
Preclinical Safety Packages — Chemistry and toxicology files now carry as much regulatory risk as clinical data. The FDA placed a partial clinical hold on PepGen's Phase 2 FREEDOM2-DM1 trial in March 2026 over previously submitted preclinical pharmacology and toxicology studies, not clinical safety. Developers of newer conjugate and peptide-linked designs face similar scrutiny. Expect longer IND-enabling programs for novel delivery chemistries.
Late Diagnosis Limits Uptake — A drug can't treat a patient who hasn't been diagnosed. Transthyretin cardiomyopathy, familial chylomicronemia and many neuromuscular disorders often go unrecognised for months or years, and patient groups such as Cardiomyopathy UK cite diagnosis as the main barrier to access. NICE estimated around 1,500 patients in England and Wales eligible for vutrisiran in ATTR-CM.
Price Pressure on Wider Labels — Wider labels mean lower list prices. Arrowhead set Redemplo's annual wholesale acquisition cost at about USD 60,000 and plans to keep one price across future indications, a fraction of classic rare-disease pricing. Payers will push further as sHTG and Lp(a) populations open. Arrowhead's single-price strategy for Redemplo is the model others will be measured against.
For many people, ATTR-CM affects every part of daily life, yet it is still too often overlooked or diagnosed far too late.

Where AI Fits Into the Oligonucleotide Therapeutics Market
AI is moving into sequence design, where the choice among thousands of candidate siRNA and antisense sequences decides potency, off-target risk and duration. In June 2026 Alnylam signed a collaboration worth up to about USD 2 billion with Inceptive to design siRNA molecules with machine learning. In April 2025 Eli Lilly signed a deal with Creyon Bio worth more than USD 1 billion in milestones for AI and quantum-chemistry-guided oligonucleotide design.
For developers, better in-silico screening means fewer synthesis-and-test cycles and faster lead selection, and modelling can flag hepatotoxicity or immune-stimulation risk before animal studies. Manufacturers are applying process analytics to coupling efficiency and purification yield, where small gains cut cost per gram. Expect AI-designed sequences to reach first-in-human trials before 2028 and to shorten discovery timelines across the siRNA pipeline.
Oligonucleotide Therapeutics Market: Segmentation
The Global Oligonucleotide Therapeutics market is segmented by Type, Application, Route of Administration, End User.
By Type
Two approvals in under a year, Arrowhead's Redemplo siRNA in November 2025 and Ionis's sHTG label for Tryngolza in June 2026, show how fast the two leading chemistries now compete for the same patients. Antisense Oligonucleotides remain the dominant type at 44.0% of 2025 revenue (USD 2,956.1 Mn), built on Spinraza, Wainua, Tryngolza and the exon-skipping PMOs. Antisense revenue dipped from USD 3,264.4 Mn in 2024 as older SMA and DMD products met gene-therapy and oral competition. siRNA holds 36.0% (USD 2,418.7 Mn) and compounds at 13.76% a year to USD 8,781.3 Mn by 2035, overtaking antisense. The fastest-growing type is Splice-switching oligonucleotides, microRNA mimics and inhibitors, at a 19.13% CAGR from a small base of USD 268.7 Mn, helped by conjugated exon skippers such as Dyne's z-rostudirsen, filed with the FDA in May 2026.
- Antisense Oligonucleotides: Gapmer antisense, Ligand-conjugated (GalNAc/LICA) antisense, Steric-blocking antisense
- siRNA: GalNAc-conjugated siRNA, Lipid nanoparticle siRNA, CNS-targeted siRNA
Year-on-Year Oligonucleotide Therapeutics Market Revenue By Type (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Antisense Oligonucleotides | 3,107.8 | 3,264.4 | 2,956.1 |
| siRNA | 1,790.5 | 1,965.7 | 2,418.7 |
| Aptamers | 600.3 | 609.4 | 671.9 |
| CpG Oligonucleotides | 302.4 | 357.3 | 403.1 |
| Splice-switching oligonucleotides, microRNA mimics and inhibitors | 182.6 | 211.4 | 268.7 |

By Application
Oligonucleotide labels are moving from ultra-rare conditions into common cardiometabolic disease, and the application mix is shifting with them. Neurological Disorders are the dominant application at 32.0% of 2025 revenue (USD 2,149.9 Mn), anchored by intrathecal antisense for spinal muscular atrophy and ALS and growing at 13.51% a year to USD 7,633.7 Mn by 2035. Oncology follows at 28.0% (USD 1,881.2 Mn) but grows more slowly, at 8.15%. Cardiometabolic Disease is the fastest-growing application, at a 16.19% CAGR from USD 1,209.3 Mn to USD 5,423.5 Mn, overtaking oncology before 2035 as triglyceride and LDL-cholesterol drugs reach millions of eligible adults. Ionis's June 2026 approval of Tryngolza for the more than 3 million Americans with severe hypertriglyceridemia is the clearest example of that shift.
Year-on-Year Oligonucleotide Therapeutics Market Revenue By Application (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Neurological Disorders | 1,761.9 | 1,968.8 | 2,149.9 |
| Oncology | 1,462.1 | 1,593.3 | 1,881.2 |
| Cardiometabolic Disease | 1,250.0 | 1,288.2 | 1,209.3 |
| Rare Genetic Disease | 1,066.7 | 1,052.9 | 940.6 |
| Ophthalmic, infectious and autoimmune diseases | 442.9 | 505.0 | 537.5 |
By Route of Administration
Dosing convenience has become a competitive weapon, because a quarterly or monthly self-injection beats a clinic infusion for a chronic disease. Subcutaneous administration is the dominant route at 51.9% of 2025 revenue (USD 3,485.3 Mn), since GalNAc-conjugated siRNA and ligand-conjugated antisense are given under the skin every one to six months. Intrathecal delivery is the fastest-growing route, at an 18.47% CAGR from USD 806.2 Mn to USD 4,390.3 Mn by 2035, as CNS antisense and siRNA programs move into larger neurological populations. Intravenous revenue grows at 14.89% to USD 7,001.3 Mn, carried by antibody-oligonucleotide conjugates that reach muscle. Biogen's March 2026 FDA approval of a high-dose Spinraza regimen shows that the intrathecal route is still being optimised, not abandoned.
Year-on-Year Oligonucleotide Therapeutics Market Revenue By Route of Administration (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Subcutaneous | 3,701.6 | 3,634.9 | 3,485.3 |
| Intravenous | 1,253.2 | 1,490.3 | 1,746.8 |
| Intrathecal | 474.1 | 608.5 | 806.2 |
| Intravitreal, intramuscular, intranasal and inhaled routes | 554.7 | 674.5 | 680.2 |
By End User
Manufacturing capacity, not just clinical demand, now shapes where oligonucleotide spending flows. Hospitals & Specialty Clinics are the dominant end user at 53.4% of 2025 revenue (USD 3,590.2 Mn), because intrathecal, intravenous and first-dose subcutaneous treatments are still started under specialist supervision. Their growth is the slowest, at 6.88% a year, as more patients move to home self-injection. Biopharma Manufacturers are the fastest-growing end user, at a 17.35% CAGR from USD 2,176.2 Mn to USD 10,779.6 Mn by 2035, which makes them the largest end user by the end of the forecast. Academic & Research Institutes hold 14.2% (USD 952.1 Mn). ST Pharm's KRW 89.7 billion oligonucleotide API order in March 2026, its largest single contract, shows the scale of outsourced manufacturing demand.
Year-on-Year Oligonucleotide Therapeutics Market Revenue By End User (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Hospitals & Specialty Clinics | 3,715.2 | 3,705.6 | 3,590.2 |
| Biopharma Manufacturers | 1,609.0 | 1,899.2 | 2,176.2 |
| Academic & Research Institutes | 659.4 | 803.4 | 952.1 |


Oligonucleotide Therapeutics Market: Production & Volume Analysis, 2025
Vectomat Insights estimates that about 1.71 million patients received an oligonucleotide therapeutic in 2025. The volume-value split is stark. CpG Oligonucleotides account for 90.8% of patients (about 1.55 million vaccine recipients) because the CpG 1018 adjuvant is given in low-cost two-dose courses, yet the type earns only 6.0% of revenue. Antisense Oligonucleotides lead on value with 44.0% of revenue from just 1.6% of patients, about 26,900 people, at roughly USD 110,000 per patient a year. siRNA treats about 100,800 patients at around USD 24,000 each. The market-wide implied average is about USD 3,900 per patient.
| Metric | 2025 Volume (patients treated) | Share of Units |
|---|---|---|
| Total patients treated (2025) | 1,707,100 | 100.0% |
| Antisense Oligonucleotides | 27,314 | 1.6% |
| siRNA | 100,719 | 5.9% |
| Aptamers | 27,314 | 1.6% |
| CpG Oligonucleotides | 1,550,047 | 90.8% |
| Splice-switching oligonucleotides, microRNA mimics and inhibitors | 1,707 | 0.1% |
Reference point: Biogen — Reported that more than 14,000 people had been treated with Spinraza (nusinersen) worldwide, including more than 5,500 adults, based on commercial and early-access patients (June 2024).
Oligonucleotide Therapeutics Market: Competitive Landscape
Approvals rather than scale decide position in this market. Two platform companies, Alnylam in siRNA and Ionis in antisense, have built most of the commercial science and now launch drugs themselves, while large pharmaceutical companies hold the rest of the approved portfolio through partnerships and acquisitions. The specialist tier is crowded and well funded, and its focus has shifted from new targets to delivery: antibody conjugates, muscle and CNS targeting. The foundational tier is small, as only a handful of CDMOs can make oligonucleotide API at commercial scale. Key players include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Biogen, Novartis, Sanofi, AstraZeneca, Astellas Pharma, Nippon Shinyaku, Arrowhead Pharmaceuticals, Wave Life Sciences, Dyne Therapeutics, City Therapeutics, ST Pharm and Bachem, among others.
| Company | HQ Country | Primary Focus | Key Strategy | Notable Recent Action |
|---|---|---|---|---|
| Ionis Pharmaceuticals | United States | Antisense oligonucleotides (LICA and gapmer chemistries) in cardiometabolic, neurology and rare disease | Moving from licensor to independent commercial launches in prevalent diseases | Received FDA approval of Tryngolza (olezarsen) for severe hypertriglyceridemia in June 2026 |
| Alnylam Pharmaceuticals | United States | GalNAc-conjugated and CNS-targeted siRNA, led by the Amvuttra TTR franchise | Alnylam 2030 plan: durable ATTR leadership, new siRNA indications and lower-cost manufacturing | Announced a USD 250 million investment in December 2025 to add its siRELIS enzymatic-ligation platform at Norton, Massachusetts |
| Sarepta Therapeutics | United States | PMO exon-skipping antisense for Duchenne muscular dystrophy, plus an siRNA pipeline | Converting accelerated approvals to traditional approval with real-world evidence | Completed the ESSENCE confirmatory study of Amondys 45 and Vyondys 53 in November 2025; the primary endpoint was not met |
| Biogen | United States | Intrathecal antisense for spinal muscular atrophy (Spinraza) and SOD1 ALS (Qalsody) | Extending the SMA franchise with high-dose and next-generation antisense | Received FDA approval of a high-dose Spinraza (nusinersen) regimen in March 2026 |
| Novartis | Switzerland | siRNA (Leqvio), antisense (pelacarsen) and antibody-oligonucleotide conjugates | Building an xRNA platform through acquisition and China licensing | Agreed in October 2025 to acquire Avidity Biosciences for about USD 12.0 billion and completed the deal in February 2026 |
| Sanofi | France | siRNA for hemophilia (Qfitlia) and the CpG 1018-adjuvanted vaccine Heplisav-B | Acquiring and in-licensing marketed RNA and adjuvant assets | Agreed in December 2025 to acquire Dynavax Technologies for about USD 2.2 billion; the deal completed in February 2026 |
| AstraZeneca | United Kingdom | Antisense for transthyretin amyloidosis (Wainua/Wainzua, partnered with Ionis) | Co-commercialising with Ionis and testing expansion into ATTR cardiomyopathy | Reported in July 2026 that the CARDIO-TTRansform Phase III trial of eplontersen in ATTR-CM missed its primary endpoint |
| Astellas Pharma | Japan | Intravitreal aptamer Izervay (avacincaptad pegol) for geographic atrophy | Global expansion of its geographic atrophy franchise | Received approval in Japan for Izervay in September 2025, the country's first geographic atrophy treatment |
| Nippon Shinyaku | Japan | PMO exon-skipping antisense for Duchenne muscular dystrophy (Viltepso, brogidirsen) | Building a DMD portfolio across exons through NCNP co-discovery and partnering | Presented five-year brogidirsen data for exon 44 DMD at the World Muscle Society congress in October 2026 |
| Arrowhead Pharmaceuticals | United States | TRiM-platform siRNA for cardiometabolic and pulmonary disease | First independent launch, then label expansion into severe hypertriglyceridemia | Received FDA approval of Redemplo (plozasiran) for familial chylomicronemia syndrome in November 2025 |
| Wave Life Sciences | Singapore | Stereopure antisense, GalNAc-siRNA and RNA editing | Moving its siRNA platform into obesity with WVE-007 | Reported six-month INLIGHT Phase 1 data for WVE-007 in March 2026, with a 14.3% placebo-adjusted cut in visceral fat after one dose |
| Dyne Therapeutics | United States | Fab-conjugated oligonucleotides for muscle diseases (FORCE platform) | Extrahepatic delivery to muscle and CNS through transferrin-receptor targeting | Submitted a BLA for accelerated approval of z-rostudirsen in exon 51 DMD in May 2026 |
| City Therapeutics | United States | Next-generation RNAi for tissues beyond the liver | Extrahepatic siRNA delivery, with a CNS partnership with Biogen | Raised a USD 99.5 million Series B led by Sofinnova Investments and Viking Global Investors in June 2026 |
| ST Pharm | South Korea | Contract development and manufacturing of oligonucleotide APIs | Scaling capacity at a second Banwol plant to become a top global oligonucleotide CDMO | Won a KRW 89.7 billion oligonucleotide API order in March 2026, its largest single contract |
| Bachem | Switzerland | Contract manufacturing of peptide and oligonucleotide APIs | Multi-site capacity expansion for large-volume oligonucleotide supply | Announced plans in July 2026 for a large-scale production facility at Sisslerfeld, Switzerland |
Three strategic themes dominate. First, big pharma is buying delivery technology: Novartis's USD 12.0 billion Avidity deal and Sanofi's USD 2.2 billion Dynavax deal both closed in 2026. Second, platform companies are going direct, with Ionis and Arrowhead running their own cardiometabolic launches. Third, manufacturing is turning into a competitive variable, as Alnylam, ST Pharm and Bachem commit capital to enzymatic and large-scale synthesis.

Oligonucleotide Therapeutics Market: From Raw Material to Delivery
Phosphoramidites, Monomers and Conjugation Reagents — Every oligonucleotide starts as protected nucleoside phosphoramidites, modified sugars such as 2'-MOE and 2'-fluoro, and conjugation ligands such as GalNAc. Supply is concentrated among a few specialty chemical makers, and purity specifications are tight because each coupling step multiplies impurities. Large solvent volumes and acetonitrile use make this stage a cost and sustainability pressure point. Enzymatic ligation, which builds siRNA from shorter fragments, aims to cut both starting material and solvent use. Key Players: Alnylam Pharmaceuticals (siRELIS enzymatic-ligation platform, December 2025).
API Synthesis, Purification and Fill-Finish — Solid-phase synthesis builds the strand one nucleotide at a time, then chromatography removes failure sequences, and this purification step is now widely seen as the main capacity bottleneck. Commercial volumes for prevalent diseases run to hundreds of kilograms a year, far above rare-disease needs. Developers either build their own plants or contract CDMOs such as ST Pharm, Bachem and Nitto Avecia. Fill-finish into prefilled syringes and autoinjectors completes the step. Key Players: ST Pharm (KRW 89.7 billion API order, March 2026).
Commercial Distribution and Specialty Pharmacy — Most oligonucleotides move through specialty distributors and specialty pharmacies under cold-chain or controlled-temperature handling. Intrathecal and intravenous products are administered in hospitals and infusion centres, while subcutaneous drugs increasingly ship to patients for home self-injection with nurse support programmes. Payer prior authorisation, rare-disease hub services and copay assistance sit at this stage and strongly shape uptake. Specialty distributors such as hub-service providers also collect the outcome and adherence data that payers increasingly ask for at renewal. Key Players: Arrowhead Pharmaceuticals (Rely On REDEMPLO patient support program, November 2025).
Oligonucleotide Therapeutics Market: Regional Analysis
North America is the dominant region with 39.76% of 2025 revenue, while Asia Pacific is the fastest-growing, and the split comes down to where approvals land first versus where manufacturing and new patient access are being added fastest. U.S. launches set the price and the label; South Korean, Japanese and Chinese capacity and approvals set the growth rate.
North America Oligonucleotide Therapeutics Market
Every major oligonucleotide approval of the past two years reached U.S. patients first, from Amvuttra in transthyretin cardiomyopathy in March 2025 to Tryngolza in severe hypertriglyceridemia in June 2026. North America holds 39.76% of the 2025 market, worth USD 2,671.5 Mn. The United States accounts for USD 2,096.2 Mn of that and is set to grow at a 10.7% CAGR to about USD 5,793.1 Mn by 2035. Arrowhead's Redemplo, priced at about USD 60,000 a year, shows how siRNA launches are now pitched at specialist cardiology rather than ultra-rare budgets. The main risk is regulatory: Sarepta's missed ESSENCE endpoint puts accelerated approvals under closer FDA review. Expect the region's lead to narrow, not disappear, as Asia Pacific capacity scales.
United States Oligonucleotide Therapeutics Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 2,096.2 Mn |
| Forecast Value (2035) | USD 5,793.1 Mn |
| CAGR (2026–2035) | 10.7% |

Europe Oligonucleotide Therapeutics Market
Health technology assessment, not marketing authorisation, decides how fast oligonucleotides reach European patients. Europe holds 26.07% of the 2025 market, worth USD 1,751.3 Mn, and Germany is the largest country market at USD 489.1 Mn, growing at a 10.3% CAGR to about USD 1,303.6 Mn by 2035. NICE's November 2025 recommendation of vutrisiran for transthyretin cardiomyopathy opened treatment to around 1,500 eligible patients in England and Wales, and the CHMP gave Redemplo a positive opinion in April 2026. Bachem's planned large-scale plant at Sisslerfeld, Switzerland, adds supply-side weight. Pricing pressure across national systems keeps the region's growth below the global 11.92% average, at a projected 10.3% for Germany.
Germany Oligonucleotide Therapeutics Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 489.1 Mn |
| Forecast Value (2035) | USD 1,303.6 Mn |
| CAGR (2026–2035) | 10.3% |

Asia Pacific Oligonucleotide Therapeutics Market
Asia Pacific is the fastest-growing region because it is adding both manufacturing capacity and newly approved patient access at the same time. The region holds 24.1% of the 2025 market, worth USD 1,619.4 Mn. South Korea is its fastest-growing country, at USD 322.5 Mn in 2025 and a 14.1% CAGR to about USD 1,206.1 Mn by 2035, while Japan, at USD 451.5 Mn, grows at 12.2%. China's NMPA approved Sanofi's siRNA Qfitlia in December 2025, and Novartis signed a licensing and option deal worth up to USD 5.2 billion with China's Argo Biopharma in September 2025. Price controls remain the main constraint. ST Pharm, which won a KRW 89.7 billion oligonucleotide API order in March 2026, is turning South Korea into the region's manufacturing base.
South Korea Oligonucleotide Therapeutics Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 322.5 Mn |
| Forecast Value (2035) | USD 1,206.1 Mn |
| CAGR (2026–2035) | 14.1% |

Latin America Oligonucleotide Therapeutics Market
Access to high-cost rare-disease drugs in Latin America often runs through public procurement and litigation rather than routine reimbursement. Latin America holds 5.3% of the 2025 market, worth USD 356.1 Mn, with Brazil the largest country. Brazil's ANVISA approved a new transthyretin cardiomyopathy indication for Alnylam's vutrisiran in 2025, following the U.S. and EU labels. Currency volatility and budget caps on imported specialty medicines are the principal restraints. Structurally, this is a follower market: revenue tracks the approval calendar of the U.S. and Europe with a lag of one to three years.
The Middle East Oligonucleotide Therapeutics Market
Gulf health systems are funding rare-disease and neurology therapies earlier than most emerging markets. The Middle East holds 3.04% of the 2025 market, worth USD 204.2 Mn, led by Saudi Arabia, the UAE and Israel. Saudi Arabia's SFDA has registered Biogen's antisense drug Qalsody for SOD1 ALS, a signal that intrathecal oligonucleotides are reaching GCC neurology centres. High rates of consanguinity in parts of the region raise the prevalence of inherited disorders that antisense and siRNA drugs target. Small patient pools and separate national tenders remain the main barriers. GCC newborn and genetic screening programmes should widen the treated population over the forecast period.
Africa Oligonucleotide Therapeutics Market
Registration, not demand, is the bottleneck in Africa: few oligonucleotide therapies have completed local review, so most patients reach them through private import or named-patient programmes. Africa holds 1.73% of the 2025 market, worth USD 116.0 Mn, concentrated in South Africa and Egypt, where private hospitals and specialist centres treat rare neuromuscular and metabolic conditions. South Africa's SAHPRA is moving toward reliance on reference-agency decisions, which could shorten review times. Out-of-pocket payment and limited genetic diagnosis keep volumes low. On VMI's forecast, Africa remains the smallest region, at about 1.7% of global revenue.


Full Country Coverage
| Region | Countries Covered |
|---|---|
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com
How Governments Are Supporting the Oligonucleotide Therapeutics Market
Regulatory-approval program — The FDA's final guidance on clinical pharmacology considerations for oligonucleotide therapeutics, issued in June 2024, sets common expectations for QT assessment, hepatic and renal impairment studies and drug-interaction work, which shortens development planning for new antisense and siRNA programs. (FDA Guidance: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics (June 2024))
Individualised therapy pathway — FDA leaders outlined a 'plausible mechanism' approval pathway in November 2025 for bespoke therapies such as N-of-1 antisense oligonucleotides, giving academic centres and nonprofits a clearer route for patient-specific drugs. (FDA plausible mechanism pathway (November 2025))
Reimbursement/funding initiative — The July 2025 budget law widened the orphan-drug exclusion from Medicare drug price negotiation, so rare-disease oligonucleotides approved for more than one orphan indication keep their protection. (One Big Beautiful Bill Act orphan-drug exclusion (July 2025))
Rare pediatric incentive — Congress reauthorised the FDA's rare pediatric disease priority review voucher program in the FY2026 funding bill in February 2026, restoring an incentive used by developers of pediatric antisense and exon-skipping drugs. (Rare Pediatric Disease Priority Review Voucher program (Give Kids a Chance Act, February 2026))
What's New in the Oligonucleotide Therapeutics Market?
Recent activity splits two ways: a run of FDA approvals that pushed oligonucleotides into cardiology and hematology, and a wave of large acquisitions and capacity bets aimed at delivery beyond the liver.
| Date | Company | Type | Description | Market Impact |
|---|---|---|---|---|
| Mar 2025 | Alnylam Pharmaceuticals | Regulatory | The FDA approved Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy, the first RNAi therapeutic shown to reduce cardiovascular death, hospitalisations and urgent heart-failure visits. [source] | Took siRNA into a cardiology population and made TTR silencing the single largest revenue source in the market. |
| Oct 2025 | Novartis / Avidity Biosciences | M&A | Novartis agreed to acquire Avidity Biosciences, developer of antibody-oligonucleotide conjugates for neuromuscular disease, for USD 72 per share, about USD 12.0 billion; the deal completed in February 2026. [source] | Set a valuation benchmark for extrahepatic delivery and brought a late-stage DMD and DM1 pipeline into big pharma. |
| Nov 2025 | Arrowhead Pharmaceuticals | Regulatory | The FDA approved Redemplo (plozasiran), a quarterly siRNA, to reduce triglycerides in adults with familial chylomicronemia syndrome, Arrowhead's first approved medicine. [source] | Created a second competitor to Ionis in APOC3 silencing and moved another platform company to commercial stage. |
| Dec 2025 | Alnylam Pharmaceuticals | Investment | Alnylam committed USD 250 million to add its siRELIS enzymatic-ligation manufacturing platform to its Norton, Massachusetts facility, expected to be fully operational by late 2027. [source] | Signals a shift from solid-phase synthesis toward lower-cost enzymatic manufacturing for high-volume siRNA. |
| Jun 2026 | Ionis Pharmaceuticals | Regulatory | The FDA approved Tryngolza (olezarsen) as the first therapy to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, with U.S. launch in July 2026. [source] | Opened a U.S. population of more than 3 million adults to an antisense drug and gave Ionis its first wholly owned launch in a prevalent disease. |
| Sep 2026 | Novartis / Ionis Pharmaceuticals | Other | The Lp(a)HORIZON Phase 3 outcomes trial of pelacarsen missed its primary endpoint, the first major Lp(a)-lowering outcomes trial to fail. [source] | Delays the Lp(a) opportunity and raises the bar for rival siRNA programs targeting the same biomarker. |
Research Methodology
Overall approach
The oligonucleotide therapeutics model is built bottom-up from product-level revenue. Each marketed antisense, siRNA, aptamer, CpG and splice-switching product is sized from reported net sales, royalty disclosures and collaboration revenue, then mapped to its type, application, route of administration and end user. The 2025 base of USD 6,718.5 Mn is reconciled top-down against the reported revenue of Ionis, Alnylam, Sarepta, Biogen, Novartis and the other profiled companies. The 2026–2035 forecast layers approved-label expansion, late-stage pipeline launches weighted by phase-transition probability, and patent-expiry erosion on top of that base.
Primary research
Primary interviews cover commercial and medical-affairs leads at oligonucleotide developers, manufacturing and quality heads at contract development and manufacturing organizations, hospital neurologists and cardiologists who prescribe intrathecal and subcutaneous oligonucleotides, specialty-pharmacy buyers, and market-access specialists in the U.S., Germany, Japan and South Korea. Interviews test treated-patient volumes, dosing intervals, net pricing after rebates and the timing of pipeline launches such as the Lp(a) and hypertriglyceridemia programs.
Secondary research
Secondary research draws on company annual reports, 10-K and 20-F filings, quarterly earnings calls and investor-day materials; FDA, EMA, PMDA and NMPA approval records and product labels; ClinicalTrials.gov registrations for Phase 2 and Phase 3 programs; peer-reviewed literature on oligonucleotide chemistry and delivery; and published epidemiology for target conditions such as spinal muscular atrophy, transthyretin amyloidosis and elevated lipoprotein(a).
Data validation
Sub-segment values in every dimension are reconciled to the 2025 base-year total of USD 6,718.5 Mn, and the six regional shares are checked to sum to 100%. Country values for the United States, Germany, Japan and South Korea are checked against their regional totals. Product-level revenue is cross-checked against reported company revenue, and the treated-patient volume model is checked against disclosed patient counts and net price per patient. Outliers trigger a second round of analyst review before the forecast is locked.
Market Coverage Definitions
How this report defines the scope of the Oligonucleotide Therapeutics Market: what each segment and sub-segment includes.
| Segment | Market Coverage Definition |
|---|---|
| By Type | Segments the market by the class of oligonucleotide molecule, covering antisense oligonucleotides, siRNA, aptamers, CpG oligonucleotides, and other oligonucleotide classes. |
| By Application | Segments the market by the therapeutic area treated, covering neurological disorders, oncology, cardiometabolic disease, rare genetic disease, and other applications. |
| By Route of Administration | Segments the market by how the therapy is delivered to the patient, covering subcutaneous, intravenous, intrathecal, and other routes of administration. |
| By End User | Segments the market by the type of organization administering or developing oligonucleotide therapies, covering hospitals and specialty clinics, biopharma manufacturers, and academic and research institutes. |
By Type
| Sub-Segment | Market Coverage Definition |
|---|---|
| Antisense Oligonucleotides | Short synthetic DNA or RNA-like strands designed to bind messenger RNA and block or modify protein production, the largest type category given their broad application across neurological, cardiometabolic, and rare genetic disease indications. |
| siRNA | Small interfering RNA molecules that trigger the natural RNA interference pathway to silence a target gene's expression, increasingly used for chronic diseases requiring infrequent maintenance dosing. |
| Aptamers | Short single-stranded DNA or RNA molecules that fold into specific three-dimensional shapes to bind a target protein directly, functioning similarly to an antibody without being one. |
| CpG Oligonucleotides | Synthetic oligonucleotides containing unmethylated CpG motifs that activate the immune system through toll-like receptor signaling, used mainly as vaccine adjuvants and immunotherapy agents. |
| Others | Additional oligonucleotide classes and formats, including gapmers, splice-switching oligonucleotides, and decoy oligonucleotides. |
By Application
| Sub-Segment | Market Coverage Definition |
|---|---|
| Neurological Disorders | Oligonucleotide therapies targeting neurological and neuromuscular conditions, the largest application given the number of approved and late-stage antisense and RNAi programs addressing genetically defined neurological diseases. |
| Oncology | Oligonucleotide therapies in development or approved for cancer treatment, including programs targeting oncogene expression and tumor-associated pathways. |
| Cardiometabolic Disease | Oligonucleotide therapies addressing lipid disorders, hypertension, and related cardiometabolic conditions, an area where several siRNA and antisense therapies have reached approval for chronic, infrequent-dosing treatment. |
| Rare Genetic Disease | Oligonucleotide therapies targeting rare, genetically defined conditions, including hereditary angioedema, transthyretin amyloidosis, and other monogenic diseases where oligonucleotide approaches can directly address the underlying genetic mechanism. |
| Others | Additional applications, including infectious disease and ophthalmic indications. |
By Route of Administration
| Sub-Segment | Market Coverage Definition |
|---|---|
| Subcutaneous | Injectable administration under the skin, the most common route for approved oligonucleotide therapies given its suitability for patient or caregiver self-administration and infrequent dosing schedules. |
| Intravenous | Administration directly into the bloodstream, typically used for therapies requiring controlled infusion or higher dose volumes delivered in a clinical setting. |
| Intrathecal | Administration directly into the spinal fluid, used for oligonucleotide therapies targeting the central nervous system that would otherwise not effectively cross the blood-brain barrier. |
| Others | Additional routes of administration, including intravitreal delivery for ophthalmic applications and oral delivery approaches still in earlier stages of development. |
By End User
| Sub-Segment | Market Coverage Definition |
|---|---|
| Hospitals & Specialty Clinics | Hospitals and specialty treatment clinics administering oligonucleotide therapies to patients, the largest end-user group given that most approved oligonucleotide therapies require administration or monitoring in a clinical setting. |
| Biopharma Manufacturers | Pharmaceutical and biotechnology companies developing and manufacturing oligonucleotide therapeutics, including both commercial-stage companies and those advancing earlier-stage pipeline programs. |
| Academic & Research Institutes | Universities and research institutions conducting oligonucleotide therapeutic research, including early discovery work and investigator-initiated clinical studies. |
Market Assessment Framework
The four-step framework used to size and validate the Oligonucleotide Therapeutics market.
- 1
Bottom-Up Approach
Market value is built up from individually identified oligonucleotide products across antisense oligonucleotides, siRNA, aptamers, and CpG oligonucleotides, starting with commercially approved products and products in late-stage development. Revenue for each product is estimated from treated patient volume, per-treatment pricing, and reimbursement coverage, then aggregated upward to the type, application, and total market level.
- 2
Volume-Based Assessment
Treated patient volume is estimated separately by application, since neurological disorders, oncology, cardiometabolic disease, and rare genetic disease carry different eligible patient populations and diagnosis rates. Dosing frequency is also modeled by route of administration, since subcutaneous, intravenous, and intrathecal products follow different treatment schedules and per-patient consumption patterns.
- 3
Price & Revenue Benchmarking
Per-treatment pricing for antisense oligonucleotides, siRNA therapies, and aptamers is benchmarked against publicly disclosed list prices and payer coverage decisions, adjusted for regional reimbursement differences. Benchmarking distinguishes between chronic, repeat-dosing therapies and products with less frequent maintenance dosing, which follow different revenue trajectories over a patient's treatment course.
- 4
Market Validation & Triangulation
Estimates built from the bottom-up and volume-based approaches are cross-checked against company-reported product sales, regulatory approval and designation decisions, and publicly announced manufacturing capacity, acquisition, and funding activity affecting oligonucleotide therapeutic development. Discrepancies beyond an acceptable range are investigated and reconciled before the estimate is finalized.
Specialized Analyst Insights
Large pharmaceutical companies are increasingly acquiring their way into newer oligonucleotide delivery technologies rather than building them internally. Novartis's roughly $12 billion agreement to acquire Avidity Biosciences brought it directly into antibody oligonucleotide conjugates, a delivery approach distinct from the lipid nanoparticle and GalNAc conjugate technologies that dominate approved siRNA and antisense therapies today. The size of the deal signals that extrahepatic and tissue-targeted delivery, not just new therapeutic targets, is now a priority acquisition criterion for large pharma in this space.
Manufacturing capacity is becoming a visible competitive variable as more oligonucleotide therapies reach commercial scale. Alnylam's $250 million investment in its enzymatic ligation siRELIS platform reflects a broader industry recognition that traditional solid-phase oligonucleotide synthesis may struggle to meet demand as more products launch and existing products expand into larger patient populations. Companies investing early in next-generation manufacturing technology may gain a durable cost and capacity advantage over competitors still relying on conventional synthesis routes.
Preclinical toxicology and pharmacology data packages remain a meaningful source of regulatory risk even for oligonucleotide programs with clean early clinical safety signals. The FDA's partial hold on PepGen's FREEDOM2-DM1 trial, which cited questions about preclinical studies rather than blinded clinical data, is a reminder that oligonucleotide developers face regulatory scrutiny on chemistry and nonclinical safety that can affect trial timelines independent of how a therapy is performing in patients.
Extrahepatic delivery, extending oligonucleotide therapies beyond the liver to tissues such as the central nervous system, heart, lungs, and tumors, continues to attract significant new capital. City Therapeutics' $99.5 million Series B, backed by both existing and new institutional investors, and its existing up-to-$1 billion Biogen partnership for a central nervous system program, point to continued investor appetite for platforms that can move oligonucleotide therapeutics beyond their traditional liver-focused comfort zone.
Regional Regulations
Regulatory authorities and requirements across 9 jurisdictions
| Region | Key Regulatory Authorities / Frameworks | Government Regulations and Regulatory Considerations |
|---|---|---|
| North AmericaU.S. | U.S. FDA | Oligonucleotide therapies are reviewed as biologics or drugs through the FDA's standard approval pathways, with many programs qualifying for orphan drug designation, breakthrough therapy designation, or accelerated approval given the rare and genetic disease focus of much of the pipeline. The FDA has also recognized emerging manufacturing technologies for oligonucleotide synthesis through its Emerging Technology Program. |
| Europe | European Medicines Agency | Oligonucleotide therapies are reviewed by the EMA under the centralized authorization procedure, with orphan medicinal product designation available for rare genetic disease programs. The EMA's Committee for Medicinal Products for Human Use issues opinions that typically precede European Commission marketing authorization decisions. |
| Asia PacificJapan | MHLW, PMDA | Japan's Pharmaceuticals and Medical Devices Agency reviews oligonucleotide therapies under the Pharmaceuticals and Medical Devices Act, with the Sakigake designation system available to accelerate review of innovative therapies including novel oligonucleotide modalities. |
| Asia PacificChina | NMPA | China's NMPA regulates oligonucleotide therapeutics as biologics, with breakthrough therapy and priority review pathways available for innovative therapies addressing unmet medical needs, including rare genetic disease programs. |
| Asia PacificIndia | CDSCO | Oligonucleotide therapies imported or developed for the Indian market are regulated under India's New Drugs and Clinical Trials Rules, administered by the CDSCO, with accelerated approval provisions available for drugs addressing serious conditions with unmet medical need. |
| Asia PacificSouth Korea | MFDS | South Korea's Ministry of Food and Drug Safety regulates oligonucleotide therapeutics as biologics, with orphan drug designation and accelerated review pathways available for rare genetic disease programs. |
| Latin AmericaBrazil | ANVISA | Oligonucleotide therapies are regulated as biological products by ANVISA, with priority review provisions available for therapies addressing rare diseases and unmet medical need. |
| Middle East | National health product regulatory authorities, GCC frameworks | Oligonucleotide therapeutic regulation continues to develop across the region, with approval generally following prior authorization in the United States, Europe, or Japan. |
| Global / International | ICH | ICH guidelines support harmonized standards for oligonucleotide drug substance characterization, impurity assessment, and quality control, supporting a more consistent global regulatory pathway for oligonucleotide therapeutics as the modality matures. |
Strategic Activities
5 strategic developments shaping the Oligonucleotide Therapeutics Market
| Date | Company / Companies | Development Type | Development and Impact on Market |
|---|---|---|---|
| Aug 2025 | Ionis Pharmaceuticals | Regulatory Approval | The FDA approved Dawnzera (donidalorsen), a ligand-conjugated antisense oligonucleotide targeting prekallikrein mRNA, for the prophylactic treatment of hereditary angioedema. The approval added a new antisense therapy to the rare genetic disease segment, extending Ionis's commercial antisense portfolio beyond its existing approved products. [source] |
| Oct 2025 | Novartis, Avidity Biosciences | Acquisition | Novartis agreed to acquire Avidity Biosciences for $72 per share in cash, valuing the deal at roughly $12.0 billion on a fully diluted basis. Avidity develops antibody oligonucleotide conjugates, a newer oligonucleotide delivery approach, with its lead program del-zota in development for Duchenne muscular dystrophy patients amenable to exon 44 skipping. [source] |
| Dec 2025 | Alnylam Pharmaceuticals | Capacity Expansion | Alnylam announced a $250 million investment to add its siRELIS enzymatic ligation manufacturing platform to its Norton, Massachusetts facility, expected to be fully operational by late 2027. The platform joins short RNA fragments into complete siRNA molecules using fewer starting materials and less solvent than traditional synthesis, increasing capacity to support Alnylam's growing RNAi pipeline. [source] |
| Mar 2026 | PepGen | Clinical Hold | The FDA placed a partial clinical hold on PepGen's Phase 2 FREEDOM2-DM1 trial of PGN-EDODM1, an oligonucleotide therapy for myotonic dystrophy type 1, citing questions about previously submitted preclinical pharmacology and toxicology studies rather than clinical safety data. No U.S. patients had been enrolled in the trial at the time of the hold, and dosing continued in Canada and the UK. [source] |
| Jun 2026 | City Therapeutics | Funding | City Therapeutics, an RNAi-focused biotech co-founded by former Alnylam CEO John Maraganore, raised a $99.5 million Series B led by new investors Sofinnova Investments and Viking Global Investors, with existing backers Regeneron Ventures, ARCH Venture Partners, and Rock Springs Capital also participating. The funding supports a platform designed to extend siRNA delivery to tissues beyond the liver. [source] |
Related Analysis
Blog · PharmaceuticalsIn Oligonucleotide Therapeutics, the Money Has Moved from Chemistry to Delivery
A $12 billion acquisition, a $250 million manufacturing bet, and a fresh Series B all point the same direction: getting an oligonucleotide molecule to work is no longer the hard part. Getting it to the right tissue, and making enough of it, is.
Read the article →Table of Contents: Oligonucleotide Therapeutics Market Report
14 chapters · 98 tables & 72 figures. Expand a chapter to see its sub-sections.
Introduction
- Report Description and Scope
- Market Definition and Oligonucleotide Classes Covered
Research Methodology
- Research Approach
- Primary and Secondary Research
- Data Validation and Triangulation
Executive Summary
Oligonucleotide Therapeutics Market Overview and Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Market Challenges
- Role of AI in Oligonucleotide Design and Manufacturing
- Value Chain: From Raw Material to Delivery
Oligonucleotide Therapeutics Market: Segmentation, By Type
- Antisense Oligonucleotides
- siRNA
- Aptamers
- CpG Oligonucleotides
- Splice-switching oligonucleotides, microRNA mimics and inhibitors
- Production and Volume Analysis, By Type, 2025 (patients treated)
Oligonucleotide Therapeutics Market: Segmentation, By Application
- Neurological Disorders
- Oncology
- Cardiometabolic Disease
- Rare Genetic Disease
- Ophthalmic, infectious and autoimmune diseases
Oligonucleotide Therapeutics Market: Segmentation, By Route of Administration
- Subcutaneous
- Intravenous
- Intrathecal
- Intravitreal, intramuscular, intranasal and inhaled routes
Oligonucleotide Therapeutics Market: Segmentation, By End User
- Hospitals & Specialty Clinics
- Biopharma Manufacturers
- Academic & Research Institutes
Oligonucleotide Therapeutics Market: Regional Analysis
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East
- Africa
Oligonucleotide Therapeutics Market: Competitive Landscape
- Market Share Analysis, 2025
- Competitive Positioning Matrix
- Strategic Developments: M&A, Licensing and Capacity
Company Profiles
- Ionis Pharmaceuticals
- Alnylam Pharmaceuticals
- Sarepta Therapeutics
- Biogen
- Novartis
- Sanofi
- AstraZeneca
- Astellas Pharma
- Nippon Shinyaku
- Arrowhead Pharmaceuticals
- Wave Life Sciences
- Dyne Therapeutics
- City Therapeutics
- ST Pharm
- Bachem
Regulatory and Policy Environment
- FDA Guidance on Oligonucleotide Clinical Pharmacology
- Orphan Drug Pricing Provisions
- EMA, PMDA and NMPA Approval Pathways
Pipeline and Clinical Development Outlook
Appendix
List of Tables (selected)
- Oligonucleotide Therapeutics Market Size, 2023–2035 (USD Million)
- Year-on-Year Oligonucleotide Therapeutics Market Revenue By Type (2023–2025, USD Million)
- Year-on-Year Oligonucleotide Therapeutics Market Revenue By Application (2023–2025, USD Million)
- Year-on-Year Oligonucleotide Therapeutics Market Revenue By Route of Administration (2023–2025, USD Million)
- Year-on-Year Oligonucleotide Therapeutics Market Revenue By End User (2023–2025, USD Million)
- Oligonucleotide Therapeutics Production & Volume, By Type, 2025 (patients treated)
- Oligonucleotide Therapeutics Market Size, By Region, 2025 (USD Million)
- North America Oligonucleotide Therapeutics Market, By Country, 2023–2035 (USD Million)
- U.S. Oligonucleotide Therapeutics Market, By Type, 2023–2035 (USD Million)
- Europe Oligonucleotide Therapeutics Market, By Country, 2023–2035 (USD Million)
- Germany Oligonucleotide Therapeutics Market, By Application, 2023–2035 (USD Million)
- Asia Pacific Oligonucleotide Therapeutics Market, By Country, 2023–2035 (USD Million)
- South Korea Oligonucleotide Therapeutics Market, By End User, 2023–2035 (USD Million)
- Latin America Oligonucleotide Therapeutics Market, By Country, 2023–2035 (USD Million)
- The Middle East Oligonucleotide Therapeutics Market, By Country, 2023–2035 (USD Million)
- Africa Oligonucleotide Therapeutics Market, By Country, 2023–2035 (USD Million)
- Key Companies: Primary Focus, Strategy and Recent Actions
- Recent Developments in the Oligonucleotide Therapeutics Market, 2025–2026
List of Figures (selected)
- Oligonucleotide Therapeutics Market Size, 2025–2035 (USD Million)
- Oligonucleotide Therapeutics Market: Drivers, Restraints, Opportunities & Challenges
- Oligonucleotide Therapeutics Market Share by Region, 2025
- Oligonucleotide Therapeutics Market — Segmentation Overview
- Oligonucleotide Therapeutics Market Share, By Type, 2025 (%)
- Oligonucleotide Therapeutics Market Share, By End User, 2025 (%)
- Oligonucleotide Therapeutics Market — Type Mix by Region
- Oligonucleotide Therapeutics Market — Competitive Landscape
- Oligonucleotide Therapeutics Market — At a Glance
- United States Oligonucleotide Therapeutics Market Size, USD Million
- Germany Oligonucleotide Therapeutics Market Size, USD Million
- South Korea Oligonucleotide Therapeutics Market Size, USD Million
You May Also Be Interested In
RNA Therapeutics Market
Parent category covering mRNA, siRNA and antisense modalities with overlapping developers and buyers.
Oligonucleotide Synthesis Market
Supply-chain relationship: phosphoramidites, synthesizers and CDMO services feeding therapeutic API production.
Rare Disease Therapeutics Market
Shared buyer persona: rare-disease specialists, orphan-drug payers and patient-advocacy networks.
Gene Therapy Market
Competing and complementary genetic medicines in SMA, DMD and other inherited disorders.
Hypertriglyceridemia Treatment Market
Same end-use indication where APOC3-silencing antisense and siRNA drugs are launching.
All VMI market research reports available in PDF. Contact sales@vectomatinsights.com
Frequently Asked Questions
What is the forecast CAGR for the oligonucleotide therapeutics market?
The market grows at an 11.92% CAGR over 2026–2035, from USD 6,718.5 Mn in 2025 to USD 20,718.1 Mn in 2035. Every type grows in absolute value over the forecast period. By type, splice-switching oligonucleotides and microRNA mimics and inhibitors grow fastest at 19.13%, CpG oligonucleotides at 16.44% and siRNA at 13.76%, while antisense grows at 8.40% from the largest base, according to Vectomat Insights.
Which application segment grows fastest?
Cardiometabolic Disease is the fastest-growing application, at a 16.19% CAGR from USD 1,209.3 Mn in 2025 to USD 5,423.5 Mn in 2035, driven by triglyceride and LDL-cholesterol drugs such as Tryngolza, Redemplo and Leqvio. Oncology, at 28.0%, grows more slowly at 8.15% a year. Neurological Disorders remain the largest application, at 32.0% of 2025 revenue and USD 7,633.7 Mn by 2035, according to Vectomat Insights.
How are oligonucleotide drugs administered?
Subcutaneous injection is the main route, at 51.9% of 2025 revenue (USD 3,485.3 Mn), because GalNAc-conjugated siRNA and antisense drugs reach the liver from a small monthly to twice-yearly dose. Intrathecal revenue rises from USD 806.2 Mn to USD 4,390.3 Mn by 2035. Intrathecal delivery for CNS diseases is the fastest-growing route at 18.47% a year, and intravenous revenue grows at 14.89% as muscle-targeting conjugates launch, according to Vectomat Insights.
Why is Asia Pacific the fastest-growing region?
Asia Pacific is adding both manufacturing capacity and patient access. South Korea, worth USD 322.5 Mn in 2025, grows at a 14.1% CAGR as ST Pharm scales oligonucleotide API production, and Japan grows at 12.2%. The region's share rises from 24.1% of global revenue in 2025. China's NMPA approved Sanofi's Qfitlia in December 2025, and Novartis signed a deal worth up to USD 5.2 billion with China's Argo Biopharma, according to Vectomat Insights.
How is the oligonucleotide manufacturing supply chain changing?
Demand for prevalent-disease drugs is outgrowing solid-phase synthesis, and purification is the main bottleneck. Alnylam is investing USD 250 million in enzymatic-ligation manufacturing, ST Pharm won a KRW 89.7 billion API order in March 2026 and Bachem plans a large-scale plant in Switzerland. New capacity typically takes two to three years to qualify. Biopharma Manufacturers grow at 17.35% a year to USD 10,779.6 Mn by 2035, according to Vectomat Insights.
What opportunities exist beyond liver-targeted oligonucleotides?
Delivery to muscle, heart and the central nervous system is the main opportunity. Novartis acquired Avidity's antibody-oligonucleotide conjugates for about USD 12.0 billion, Dyne filed z-rostudirsen for Duchenne muscular dystrophy in May 2026, and City Therapeutics raised USD 99.5 million for extrahepatic RNAi. These programs target muscle and CNS diseases with few treatments. Obesity is another frontier, with Wave's WVE-007 in development, according to Vectomat Insights.
How was the oligonucleotide therapeutics market sized?
The model is built bottom-up from product-level net sales and royalty disclosures, mapped to type, application, route and end user, then reconciled top-down against the reported revenue of the profiled companies. Country values are checked against regional totals. Primary interviews with developers, CDMOs, prescribers and market-access specialists test volumes and pricing, and segments and regions are reconciled to the 2025 total, according to Vectomat Insights.
Access the Complete Oligonucleotide Therapeutics Market Report
300+ pages | 98 tables & 72 figures | 2026–2035 | All 6 regions | PDF
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com
Request a free sample
Ready to go deeper? Request a free sample of the VMI Oligonucleotide Therapeutics Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.
About this report
Get a free sample of this report
Oligonucleotide Therapeutics Market